4th Quarter - Report — ALSTON & BIRD LLP for NOVARTIS CORPORATION (2017)

Firm

ALSTON & BIRD LLP

Client

NOVARTIS CORPORATION

Income

$10,000

Expenses

—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to drug policy, including reimbursement.

Foreign entity interest: To the extent that Novartis Corporation derives any benefit from legislative or executive action, so, too, does its parent corporation, Novartis AG.

Lobbyist	Covered position, as disclosed
JENNIFER L BUTLER	—
PETER M KAZON	—
Y. BRIAN LEE New	Legislative Intern, Rep. Doug Lamborn.
MARK RAYDER	—

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Medical/Disease Research/Clinical Labs MED

Issues related to drug policy, including reimbursement.

Foreign entity interest: To the extent that Novartis Corporation derives any benefit from legislative or executive action, so, too, does its parent corporation, Novartis AG.

Lobbyist	Covered position, as disclosed
JENNIFER L BUTLER	—
PETER M KAZON	—
Y. BRIAN LEE New	Legislative Intern, Rep. Doug Lamborn.
MARK RAYDER	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Medicare/Medicaid MMM

Issues related to drug policy, including reimbursement.

Foreign entity interest: To the extent that Novartis Corporation derives any benefit from legislative or executive action, so, too, does its parent corporation, Novartis AG.

Lobbyist	Covered position, as disclosed
JENNIFER L BUTLER	—
PETER M KAZON	—
Y. BRIAN LEE New	Legislative Intern, Rep. Doug Lamborn.
MARK RAYDER	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.